Eli Lilly and Company $LLY Stock Purchased by International Private Wealth Advisors LLC

International Private Wealth Advisors LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 42.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,478 shares of the company’s stock after buying an additional 1,028 shares during the period. Eli Lilly and Company comprises 1.5% of International Private Wealth Advisors LLC’s investment portfolio, making the stock its 18th largest holding. International Private Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $4,024,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of LLY. Bank of America Corp DE purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $13,522,666,000. Jupiter Topco LLC acquired a new position in Eli Lilly and Company in the 2nd quarter worth approximately $4,667,180,000. Corient Private Wealth LP acquired a new position in Eli Lilly and Company in the 2nd quarter worth approximately $764,116,000. BlackRock Inc. grew its position in Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after purchasing an additional 1,046,558 shares in the last quarter. Finally, State Street Corp grew its position in Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after purchasing an additional 605,752 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Key Eli Lilly and Company News

Investors following LLY have been watching these news items:

• Positive Sentiment: Lilly reported positive 52-week Phase 3b results for Taltz plus Zepbound in adults with psoriatic arthritis and obesity. Nearly three times as many combination-treatment patients achieved at least a 50% reduction in disease activity versus Taltz alone, potentially broadening Zepbound’s use and commercial opportunity. Article: Phase 3b Taltz and Zepbound results
• Positive Sentiment: Foundayo, Lilly’s GLP-1 weight-loss pill, was reported to have shown substantial improvement in sleep apnea, adding to the potential uses of the company’s obesity pipeline. Article: Foundayo and sleep apnea
• Negative Sentiment: Possible new U.S. drug-price negotiations could put pressure on Lilly revenue, according to a report identifying the company as facing nearer-term pricing exposure. Article: Drug-pricing risks

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the transaction, the executive vice president owned 4,137 shares in the company, valued at $5,802,225.24. This trade represents a 54.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have recently commented on the company. Bank of America reaffirmed a “buy” rating and issued a $1,497.00 target price on shares of Eli Lilly and Company in a research report on Friday, October 30th. Wells Fargo & Company upped their price target on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Jefferies Financial Group increased their price objective on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the stock a “buy” rating in a research note on Monday. Finally, TD Cowen restated a “buy” rating and set a $1,250.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,416.64.

Eli Lilly and Company Stock Up 0.4%

Eli Lilly and Company stock opened at $1,437.46 on Thursday. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,453.00. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The firm has a market cap of $1.35 trillion, a PE ratio of 46.66, a P/E/G ratio of 1.72 and a beta of 0.40. The firm’s 50 day moving average price is $1,231.13 and its two-hundred day moving average price is $1,106.42.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same quarter last year, the business posted $7.02 EPS. The company’s revenue for the quarter was up 38.6% on a year-over-year basis. On average, research analysts predict that Eli Lilly and Company will post 35.67 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 22.46%.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.